In this episode of The Canadian Investor Podcast, we do a deep dive on two companies we haven’t covered much before: Royalty Pharma and AppLovin.

We start with Royalty Pharma, a unique business that finances pharmaceutical and biotech products in exchange for future royalty streams. We break down how the business model works, why it has similarities to precious metals royalty companies like Franco-Nevada, and how investors should think about portfolio receipts, cash flow, milestone payments, drug approval risk, concentration risk and capital allocation.

We then turn to AppLovin, one of the most talked-about stocks in the market. We look at how its AI-powered mobile advertising platform works, why the company generates extremely high margins with minimal capital expenditures, and what makes the business so profitable.

We also discuss the risks facing AppLovin, including slowing growth, competition from Meta, Apple and Alphabet, concerns raised by short sellers, and why the market is having such a hard time valuing the company after a massive run-up and sharp drawdown.

Tickers discussed: RPRX, APP, FNV.TO, WPM.TO, ISRG, META, GOOGL, GOOG, TTD

Subscribe to our Our New Youtube Channel!

Check out our portfolio by going to Jointci.com